S27-1047
S27-1047 is a brain-penetrant, potent and selective BChE (eqBChE IC50 = 7.16 nM; hBChE IC50 = 296.10 nM) inhibitor and Nrf2 activator. S27-1047 can directly bind Keap1, disrupt Keap1-Nrf2 interaction (FP IC50 = 36.87 nM), enhance antioxidant enzyme expression and activate the GSH-GPX4 axis to inhibit Aβ-induced ferroptosis. S27-1047 can protect against oxidative stress and neuroinflammation. S27-1047 can be used in Alzheimer's disease research.
For research use only. We do not sell to patients.
- CAS No.: 3121876-09-0
- Formula: C25H16F2N8O3
- Molecular Weight:514.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
eqBCHE 7.16 nM (IC50) |
hBCHE 296.10 nM (IC50) |
GPX4 |
In Vitro
S27-1047 (10 μM; 0-24 h) can significantly upregulate the expression of Nrf2 downstream proteins in a time-dependent manner and the effect is more obvious in 5 to 10 h [1].
S27-1047 (10 μM; 0-24 h) shows low neurotoxicity in L02 cells , BV2 microglia cells and SH-SY5Y cells[1].
S27-1047 (1-20 μM; 6 h) can significantly increase the level of Nrf2 and its downstream protein (HO-1, NQO1 and GCLM) in a dose-dependent manner and induces a nearly 5-fold increasein Nrf2 protein expression at a concentration of 5 μM[1].
S27-1047 (10μM) exhibits antioxidant activity in an Nrf2-dependent manner[1].
S27-1047 (10 μM; 0-24 h) reveals significant nuclear accumulation of Nrf2 during 2-5 h treatment periods[1].
S27-1047 (10 μM; 2 h; 37-51 °C) induces a pronounced thermal stabilization of Keap1[1].
S27-1047 (10 μM) significantly promotes Keap1 degradation, consequently upregulating Nrf2 protein levels and effectively disrupting the Keap1-Nrf2 complexformation (FP IC50 = 36.87 nM)[1].
S27-1047 (1-20 μM; pretreatment for 2 h + co-incubation with Aβ1-42 for 24 h) demonstrates a potent, dose-dependent cytoprotective effect against H2O2-induced oxidative damage in L02 cells[1].
S27-1047 (1-20 μM; pretreatment for 2 h + co-incubation with Aβ1-42 for 24 h) demonstrates a dose-dependent cytoprotective effect against toxic Aβ fibril-induced cytotoxicity in the human neuroblastoma SH-SY5Y cells[1].
S27-1047 (10 μM; pretreatment for 24 h + co-incubation with Aβ1-42 for 24 h) significantly attenuats ROS generation without affecting cellular viability[1].
S27-1047 (10 μM) significantly inhibits the upregulation of tumor necrosis factor-alpha (TNF-α) in LPS-stimulated BV2 microglia cells[1].
S27-1047 (10 μM; pretreatment for 24 h + co-incubation with Aβ1-42 for 24 h) significantly attenuated lipid peroxidation in SH-SY5Y cells. S27-1047 robustly activates the System Xc- /GSH/GPX4 axis, a critical antioxidant pathway, leading to marked increases in GSH levels and GPX4 activity. S27-1047 can mitigate Aβ-induced ferroptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:L02 cells treated with H2O2 or Aβ 2
-
Concentration:1 μM, 5 μM, 10 μM, 20 μM
-
Incubation Time:24 h
-
Result:Markedly alleviated oxidative damage in LO2 cells and demonstrated potent cytoprotective effects in a dose-dependent manner.
-
Cell Line:SH-SY5Y cells
-
Concentration:1 μM, 5 μM, 10 μM, 20 μM
-
Incubation Time:24 h
-
Result:Alleviated oxidative damage in SH-SY5Y cells and demonstrated potent cytoprotective effects in a dose-dependent manner.
-
Cell Line:SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Increased levels of reduced lipid biomarkers.
-
Cell Line:SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Increased in GSH levels and GPX4 activity.
Parmacokinetics
In Vivo
S27-1047 (10 mg/kg; i.g.; one time) demonstrates the ability to cross the blood-brain barrier and exhibited moderate drug exposure levels within the brainin ICR mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice wereinjected Aβ1-42 peptide (10 μg) icv injection on day 1[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; once daily; days 3 to 16
-
Result:Significantly improved cognitive impairment in mice and reversed deficits in spatial learning and working memory.
Demonstrated cognitive-enhancing efficacy superior not only to the positive control drug rivastigmine but also to equidoses of monotherapy (the BChE inhibitor S06-1064 or the Nrf2 activator 6) and the combination therapy of the two.
Upregulated the expression levels of Nrf2, the antioxidant-related protein GCLM, and the ferroptosis defense-related protein GPX4 in mouse brain tissue.
-
Animal Model:ICR mouse model[1]
-
Dosage:10 mg/kg
-
Administration:i.g.; one time
-
Result:Demonstrated the ability to successfully penetrate the blood-brain barrier and exhibit moderate drug exposure levels within the brain.
Chemical Information
-
CAS No. 3121876-09-0
-
Molecular Weight 514.44
-
Formula C25H16F2N8O3
-
SMILES
O=C(NC1=CC=CC(C2=NOC(C3=CC=C(F)C=C3F)=N2)=C1)CN4C(C5=NON=C5N)=NC6=CC=CC=C46
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)